| | | Good stuff and the uplisting was nice, but the second abstract is the game changer, imho. Why? Perhaps better for mgt to save it for another day because the PR is silent on the topic, but I see that it has been mentioned to some extent on other boards. I am also not convinced that the market has digested the news and obviously I do not believe in efficient markets...here's the reason why I purchased more and more and more the last two months.
You like to play connect the dots?
Go back to see who has worked on the past studies. Now look again to see who is added to the second abstract - Jeffrey Weber. You have to look hard because his name is not mentioned in the most recent PR and it is not even listed at the top of the author list. So, what's the big deal, you ask? I guess if I was new to the game, I probably wouldn't think much of it, if I thought at all, but I am OTTG. Putting aside his reputation, among other things, when you have a chance, take a look at his disclosures (not for this abstract - you'll need to look at his older ones - hey, due your own DD like I did a long time ago!).
As many of you probably know, funding sources are a lifeblood for researchers -- now, connect those dots! |
|
